In autoimmune diseases as Type 1 diabetes, the actual treatment that provides the missing hormones is not able, however, to interrupt the underlining immunological mechanism. Importantly, novel immunotherapies are exploited to protect and rescue the remaining hormone producing cells. Among probable targets of immunotherapy, the C1858T mutation in the PTPN22 gene, which encodes for the lymphoid tyrosine phosphatase (Lyp) variant R620W, reveals an autoimmunity related pathophysiological role. Our scope was to establish new C1858T PTPN22 siRNA duplexes delivered by liposomal carriers (lipoplexes) to patients’ PBMC. Following lipoplexes treatment, CD3+ and CD3− immunotypes were efficiently transfected; cell integrity and viability were preserved. Specific target mRNA down-modulation was observed. After T cell receptor stimulation, in lipoplexes-treated PBMC Lyp function was restored by increased release of IL-2 in cultures. Results set-up the stage for ultimate trials in the treatment of autoimmunity based on the specific inhibitory targeting of C1858T PTPN22 by lipoplexes. © 2018 The Authors

Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient down-regulation of variant PTPN22 gene in T lymphocytes / Pellegrino, Marsha; Ceccacci, Francesca; Petrini, Stefania; Scipioni, Anita; De Santis, Serena; Cappa, Marco; Mancini, Giovanna; Fierabracci, Alessandra. - In: NANOMEDICINE. - ISSN 1549-9634. - (2019). [10.1016/j.nano.2018.11.001]

Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient down-regulation of variant PTPN22 gene in T lymphocytes

Scipioni, Anita;De Santis, Serena;
2019

Abstract

In autoimmune diseases as Type 1 diabetes, the actual treatment that provides the missing hormones is not able, however, to interrupt the underlining immunological mechanism. Importantly, novel immunotherapies are exploited to protect and rescue the remaining hormone producing cells. Among probable targets of immunotherapy, the C1858T mutation in the PTPN22 gene, which encodes for the lymphoid tyrosine phosphatase (Lyp) variant R620W, reveals an autoimmunity related pathophysiological role. Our scope was to establish new C1858T PTPN22 siRNA duplexes delivered by liposomal carriers (lipoplexes) to patients’ PBMC. Following lipoplexes treatment, CD3+ and CD3− immunotypes were efficiently transfected; cell integrity and viability were preserved. Specific target mRNA down-modulation was observed. After T cell receptor stimulation, in lipoplexes-treated PBMC Lyp function was restored by increased release of IL-2 in cultures. Results set-up the stage for ultimate trials in the treatment of autoimmunity based on the specific inhibitory targeting of C1858T PTPN22 by lipoplexes. © 2018 The Authors
2019
immunotherapy; lipoplexes; T1D; variant PTPN22
01 Pubblicazione su rivista::01a Articolo in rivista
Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient down-regulation of variant PTPN22 gene in T lymphocytes / Pellegrino, Marsha; Ceccacci, Francesca; Petrini, Stefania; Scipioni, Anita; De Santis, Serena; Cappa, Marco; Mancini, Giovanna; Fierabracci, Alessandra. - In: NANOMEDICINE. - ISSN 1549-9634. - (2019). [10.1016/j.nano.2018.11.001]
File allegati a questo prodotto
File Dimensione Formato  
Pellegrino_inpress_Exploiting_2018.pdf

accesso aperto

Note: https://www.sciencedirect.com/science/article/pii/S1549963418305501?via=ihub
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 1.4 MB
Formato Adobe PDF
1.4 MB Adobe PDF
Pellegrino_ArticleExploiting_2019.pdf

accesso aperto

Note: https://www.sciencedirect.com/science/article/pii/S1549963418305501?via%3Dihub
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.52 MB
Formato Adobe PDF
1.52 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1275294
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact